Next Article in Journal
Vaccine Licensure in the Absence of Human Efficacy Data
Previous Article in Journal
Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Vaccination: A Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Post-Vaccination Adverse Effects Based on Predisposing Factors
Previous Article in Special Issue
Incidence of Vaccine-Preventable Childhood Diseases in the European Union and in the European Free Trade Association Countries
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 10
Issue 3
10.3390/vaccines10030367
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?

by
Vivek P. Chavda
1 and
Vasso Apostolopoulos
2,3,*
1
Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad 380008, Gujrat, India
2
Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia
3
Immunology Program, Australian Institute for Musculoskeletal Science (AIMSS), Melbourne, VIC 3021, Australia
*
Author to whom correspondence should be addressed.
Vaccines 2022, 10(3), 367; https://doi.org/10.3390/vaccines10030367
Submission received: 17 January 2022 / Revised: 21 February 2022 / Accepted: 23 February 2022 / Published: 26 February 2022
(This article belongs to the Special Issue Vaccines for Infectious and Chronic Diseases)
Browse Figure
Versions Notes

Abstract

The Omicron variant of SARS-CoV-2 is emerging in communities where people were previously infected with SARS-CoV-2 and are now being vaccinated, or where many people have received two or three coronavirus vaccination doses. More than 130 countries around the globe have implemented booster dose programs for tackling omicron endemics. Despite early findings shows that booster doses may improve omicron protection, more research is needed to establish vaccination efficacy. This short communication tries to critically discuss the research work findings around booster dose strategy for omicron endemics.
Keywords: Omicron variant; SARS-CoV-2; booster dose; vaccine Omicron variant; SARS-CoV-2; booster dose; vaccine

Share and Cite

MDPI and ACS Style

Chavda, V.P.; Apostolopoulos, V. Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2? Vaccines 2022, 10, 367. https://doi.org/10.3390/vaccines10030367

AMA Style

Chavda VP, Apostolopoulos V. Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2? Vaccines. 2022; 10(3):367. https://doi.org/10.3390/vaccines10030367

Chicago/Turabian Style

Chavda, Vivek P., and Vasso Apostolopoulos. 2022. "Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?" Vaccines 10, no. 3: 367. https://doi.org/10.3390/vaccines10030367

APA Style

Chavda, V. P., & Apostolopoulos, V. (2022). Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2? Vaccines, 10(3), 367. https://doi.org/10.3390/vaccines10030367

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop